Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Axl

Axl

Brief Information

Name:AXL receptor tyrosine kinase
Target Synonym:EC:2.7.10.1,EC 2.7.10,UFO,AXL Transforming Sequence/Gene,AXL Oncogene,EC 2.7.10.1,JTK11,Tyro7,ARK,Tyrosine-protein kinase receptor UFO,AXL,AXL Receptor Tyrosine Kinase
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:28
Lastest Research Phase:Approved

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
AXL inhibitor Small molecule Oncology/Cancer STK11_mut NSCLC,other cancers Phase I Global

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

AXL-H5253-SPR
 Axl SPR

Human Axl, Fc Tag (Cat. No. AXL-H5253) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human GAS6, His Tag (Cat. No. GA6-H5249) with an affinity constant of 1.23 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

AXL-H5253-ELISA
 Axl ELISA

Immobilized Human GAS6, His Tag (Cat. No. GA6-H5249) at 5 μg/mL (100 μL/well) can bind Human Axl, Fc Tag (Cat. No. AXL-H5253) with a linear range of 0.1-10 ng/mL (QC tested).

Synonym Name

AXL,UFO

Background

AXL Receptor Tyrosine Kinase is also known as Tyrosine-protein kinase receptor UFO, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. AXL contains two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. AXL is highly expressed in metastatic colon tumors. AXL is activated by GAS6-binding and subsequent autophosphorylation. AXL is involved in signal transduction from the extracellular matrix into the cytoplasm by binding growth factors, and thus implicated in the stimulation of cell proliferation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx United States Carcinoma, Neuroendocrine; Thyroid Neoplasms Exelixis Inc 2012-11-29 Carcinoma, Adenosquamous; Uterine Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Gliosarcoma; Bile Duct Neoplasms; Peritoneal Neoplasms; Astrocytoma; Colorectal Neoplasms; Brain Neoplasms; Endometrial Neoplasms; Osteosarcoma; Urethral Neoplasms; Adenocarcinoma, Clear Cell; Neuroblastoma; Neurofibroma, Plexiform; Cholangiocarcinoma; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Breast Neoplasms; Carcinoma, Endometrioid; Neoplasms, Germ Cell and Embryonal; Meningioma; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Cancer, Papillary; Neoplasm Metastasis; Paraganglioma; Carcinoma, Hepatocellular; Sarcoma, Clear Cell; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Brain metastases; Lymphoma; Leukemia, Myeloid, Acute; Sarcoma, Alveolar Soft Part; Glioma; Carcinoma, Squamous Cell; Pain; Adrenal Cortex Neoplasms; Pancreatic neuroendocrine tumors (pNET); Glioblastoma; Kidney Diseases; Hepatoblastoma; Pheochromocytoma; Carcinoma, Renal Cell; Rejection of liver transplantation; Carcinoid Details
Gilteritinib Fumarate ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) Approved Astellas Pharma Inc Xospata Japan Leukemia, Myeloid, Acute Astellas Pharma Inc 2018-09-21 Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
INCB-081776 INCB-81776; INCB-081776 Phase 1 Clinical Incyte Corp Solid tumours Details
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 Phase 1 Clinical Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lung Neoplasms Details
Bemcentinib R-428; BGB-324 Phase 2 Clinical Rigel Pharmaceuticals Inc Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Pancreatic Neoplasms; Adenocarcinoma of Lung; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms; Mesothelioma; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Lymphoma, Mantle-Cell; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Glesatinib MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265 Phase 2 Clinical Mirati Therapeutics Inc Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ONO-7475 ONO-7475 Phase 2 Clinical Ono Pharmaceutical Co Ltd Leukemia; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
cancer therapeutics (BerGenBio) BGB-101; BGB-109; BGB-003; BGB-001 Phase 1 Clinical Bergenbio Details
TT-00973 TT-00973 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours Details
NPS-1034 HOPE-777; KDDF-201111-02 Neopharma Ltd Details
Enapotamab vedotin AXL-107-MMAE Phase 2 Clinical Seattle Genetics Inc, Genmab A/S Ovarian Neoplasms; Solid tumours; Neoplasms; Sarcoma; Endometrial Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
KC1036 KC1036; KC-1036 Phase 3 Clinical Beijing Konruns Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours; Digestive System Neoplasms; Sarcoma, Ewing; Thymus Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Neoplasm Metastasis Details
NTQ-2494 NTQ2494; NTQ-2494 Phase 1 Clinical Nanjing Zhengda Tianqing Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Leukemia, Myeloid, Acute Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase 2 Clinical Hec Pharm Co Ltd Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Mipasetamab uzoptirine ADCT-601; BGB-601 Phase 1 Clinical Adc Therapeutics Sa Solid tumours Details
XZB-0004 XZB-0004; SLC-0211; SLC-391 Phase 2 Clinical Xuanzhu (Shijiazhuang) Biotechnology Co Ltd Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases Details
PF-07265807 PF-07265807 Phase 1 Clinical Pfizer Inc Solid tumours; Neoplasm Metastasis Details
Dubermatinib TP-0903 Phase 1 Clinical Sumitomo Dainippon Ovarian Neoplasms; Solid tumours; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
NP-107 NP107; NP-107 Phase 1 Clinical Shanghai Nawei Biotechnology Co Ltd Solid tumours Details
Zanzalintinib XL-092 Phase 3 Clinical Exelixis Inc Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Sitravatinib MG-91516; MGCD-516; IND-155305; MG-516 Phase 3 Clinical Mirati Therapeutics Inc Breast Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Mouth Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Ureteral Neoplasms; Hepatic Insufficiency; Solid tumours; Liposarcoma; Uveal melanoma; Lung Diseases; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Kidney Neoplasms Details
AGX-0073 AGX-0073 Phase 1 Clinical Shanghai Aojian Biological Technology Co Ltd Solid tumours Details
Q-702 Q-702 Phase 2 Clinical Vichem Chemie, Max Planck Institute of Biochemistry, Lead Discovery Center GmbH Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms Details
Butylidenephthalide HK-001; LF-001 (Everfront Biotech); NSC-325307; BDPH Phase 2 Clinical Everfront Biotech Co Ltd Glioma; Amyotrophic Lateral Sclerosis Details
FC-084-CSA FC-084-CSA; FC084CSA Phase 1 Clinical Zhongshan Yinuo Weishen New Drug Research and Development Co Ltd Solid tumours Details
AB-801 AB-801 Phase 1 Clinical Arcus Biosciences Inc Neoplasms Details
BPI-9016 BPI-9016; BPI-9016M Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
CCT301-38 CCT301-38; CCT301-38 AXL Phase 2 Clinical F1 Oncology, Bioatla Carcinoma, Renal Cell; Rhinitis, Allergic, Seasonal Details
Mecbotamab vedotin BA-3011; BA3011; BA 3011 Phase 2 Clinical Bioatla Ovarian Neoplasms; Sarcoma, Synovial; Liposarcoma; Sarcoma; Osteosarcoma; Sarcoma, Ewing; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message